Andrew H Galligan Insider Trading $NVRO NEVRO CORP
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Andrew H Galligan.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Andrew H Galligan. Andrew H Galligan is Director in Diadexus, Inc. ($DDXS) and Director in OOMA INC ($OOMA) and Chief Financial Officer in NEVRO CORP ($NVRO).
Andrew H Galligan in NEVRO CORP
Trading Symbol: NVROIndustry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
Position of Andrew H Galligan: Chief Financial Officer
Holdings: 59,179 shares
Current Value: $5,523,176
Latest Transaction: Jun 08 2020
$NVRO Market Capitalization: $2.71B
$NVRO Previous Close: $93.33
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Andrew H Galligan in NEVRO CORP
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, DDXS, NVRO, OOMA
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 08 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Payment of Exercise | F | 121.53 | 2,311 | 280,856 | 59,179 | 61.5 K to 59.2 K (-3.76 %) |
Mar 03 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 8,000 | 28,800 | 33,394 | |
Mar 03 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 8,000 | 28,800 | 33,394 | |
Mar 03 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 8,000 | 28,800 | 61,490 | 53.5 K to 61.5 K (+14.96 %) |
Mar 03 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 8,000 | 28,800 | 61,490 | 53.5 K to 61.5 K (+14.96 %) |
Jan 10 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 63.23 | 17,718 | 1,120,309 | 0 | |
Jan 10 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 120.11 | 17,718 | 2,128,086 | 53,490 | 71.2 K to 53.5 K (-24.88 %) |
Jan 10 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 63.23 | 17,718 | 1,120,309 | 71,208 | 53.5 K to 71.2 K (+33.12 %) |
Jan 10 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 63.23 | 17,718 | 1,120,309 | 0 | |
Jan 10 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 120.11 | 17,718 | 2,128,086 | 53,490 | 71.2 K to 53.5 K (-24.88 %) |
Jan 10 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 63.23 | 17,718 | 1,120,309 | 71,208 | 53.5 K to 71.2 K (+33.12 %) |
Jan 08 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 63.23 | 2,782 | 175,906 | 17,718 | |
Jan 08 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 120.00 | 2,782 | 333,840 | 53,490 | 56.3 K to 53.5 K (-4.94 %) |
Jan 08 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 63.23 | 2,782 | 175,906 | 56,272 | 53.5 K to 56.3 K (+5.20 %) |
Nov 26 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 63.23 | 12,000 | 758,760 | 20,500 | |
Nov 26 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 110.39 | 12,000 | 1,324,714 | 53,490 | 65.5 K to 53.5 K (-18.32 %) |
Nov 26 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 63.23 | 12,000 | 758,760 | 65,490 | 53.5 K to 65.5 K (+22.43 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 63.23 | 12,000 | 758,760 | 32,500 | |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 63.23 | 12,000 | 758,760 | 32,500 | |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 6,522 | 117,396 | 14,941 | |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 6,522 | 117,396 | 14,941 | |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 104.75 | 1,175 | 123,075 | 53,490 | 54.7 K to 53.5 K (-2.15 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 104.75 | 1,175 | 123,075 | 53,490 | 54.7 K to 53.5 K (-2.15 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 103.85 | 10,345 | 1,074,287 | 54,665 | 65 K to 54.7 K (-15.91 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 103.85 | 10,345 | 1,074,287 | 54,665 | 65 K to 54.7 K (-15.91 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 103.31 | 7,002 | 723,369 | 65,010 | 72 K to 65 K (-9.72 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 103.31 | 7,002 | 723,369 | 65,010 | 72 K to 65 K (-9.72 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 63.23 | 12,000 | 758,760 | 72,012 | 60 K to 72 K (+20.00 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 63.23 | 12,000 | 758,760 | 72,012 | 60 K to 72 K (+20.00 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 6,522 | 117,396 | 60,012 | 53.5 K to 60 K (+12.19 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 6,522 | 117,396 | 60,012 | 53.5 K to 60 K (+12.19 %) |
Nov 05 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Payment of Exercise | F | 86.63 | 1,713 | 148,397 | 53,490 | 55.2 K to 53.5 K (-3.10 %) |
Jul 17 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 2,500 | 9,000 | 41,394 | |
Jul 17 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 2,500 | 9,000 | 55,203 | 52.7 K to 55.2 K (+4.74 %) |
May 30 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Grant | A | 0.00 | 8,564 | 0 | 52,703 | 44.1 K to 52.7 K (+19.40 %) |
Jan 08 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 1.44 | 11,004 | 15,846 | 0 | |
Jan 08 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 1.44 | 11,004 | 15,846 | 44,139 | 33.1 K to 44.1 K (+33.21 %) |
Nov 02 2018 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Payment of Exercise | F | 49.40 | 2,457 | 121,376 | 33,135 | 35.6 K to 33.1 K (-6.90 %) |
Jul 20 2018 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 1.44 | 7,400 | 10,656 | 11,004 | |
Jul 20 2018 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 1.44 | 7,400 | 10,656 | 35,592 | 28.2 K to 35.6 K (+26.25 %) |
May 16 2018 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 7,000 | 126,000 | 21,463 | |
May 16 2018 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 76.14 | 7,000 | 532,959 | 28,192 | 35.2 K to 28.2 K (-19.89 %) |
May 16 2018 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 7,000 | 126,000 | 35,192 | 28.2 K to 35.2 K (+24.83 %) |
Nov 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 7,000 | 126,000 | 35,463 | |
Nov 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | A | 76.81 | 26,000 | 1,997,060 | 26,000 | |
Nov 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 75.11 | 7,000 | 525,740 | 28,192 | 35.2 K to 28.2 K (-19.89 %) |
Nov 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 7,000 | 126,000 | 35,192 | 28.2 K to 35.2 K (+24.83 %) |
Nov 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Grant | A | 0.00 | 13,000 | 0 | 28,192 | 15.2 K to 28.2 K (+85.57 %) |
Nov 13 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 1.44 | 4,000 | 5,760 | 18,404 | |
Nov 13 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 1.44 | 4,000 | 5,760 | 15,192 | 11.2 K to 15.2 K (+35.74 %) |
Nov 03 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Payment of Exercise | F | 88.99 | 641 | 57,043 | 11,192 | 11.8 K to 11.2 K (-5.42 %) |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 204 | 3,672 | 42,463 | |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 6,144 | 22,118 | 36,286 | |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 652 | 2,347 | 43,894 | |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 82.31 | 7,000 | 576,192 | 11,833 | 18.8 K to 11.8 K (-37.17 %) |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 204 | 3,672 | 18,833 | 18.6 K to 18.8 K (+1.10 %) |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 6,144 | 22,118 | 18,629 | 12.5 K to 18.6 K (+49.21 %) |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 652 | 2,347 | 12,485 | 11.8 K to 12.5 K (+5.51 %) |
May 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 7,500 | 27,000 | 44,546 | |
May 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 76.40 | 1,306 | 99,782 | 11,833 | 13.1 K to 11.8 K (-9.94 %) |
May 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 75.55 | 2,698 | 203,826 | 13,139 | 15.8 K to 13.1 K (-17.04 %) |
May 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 74.69 | 3,496 | 261,126 | 15,837 | 19.3 K to 15.8 K (-18.08 %) |
May 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 7,500 | 27,000 | 19,333 | 11.8 K to 19.3 K (+63.38 %) |
May 11 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 1.44 | 5,000 | 7,200 | 22,404 | |
May 11 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 1.44 | 5,000 | 7,200 | 11,833 | 6.8 K to 11.8 K (+73.17 %) |
Apr 05 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 95.04 | 14,297 | 1,358,791 | 6,833 | 21.1 K to 6.8 K (-67.66 %) |
Apr 05 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 94.32 | 9,166 | 864,569 | 21,130 | 30.3 K to 21.1 K (-30.25 %) |
Apr 05 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 93.39 | 6,537 | 610,468 | 30,296 | 36.8 K to 30.3 K (-17.75 %) |
Nov 18 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | A | 87.62 | 27,333 | 2,394,917 | 27,333 | |
Nov 18 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Grant | A | 0.00 | 6,833 | 0 | 36,833 | 30 K to 36.8 K (+22.78 %) |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 4,185 | 75,330 | 42,667 | |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 3,315 | 11,934 | 59,546 | |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 87.55 | 2,906 | 254,416 | 30,000 | 32.9 K to 30 K (-8.83 %) |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 86.75 | 3,734 | 323,942 | 32,906 | 36.6 K to 32.9 K (-10.19 %) |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 85.70 | 660 | 56,563 | 36,640 | 37.3 K to 36.6 K (-1.77 %) |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 84.17 | 200 | 16,833 | 37,300 | 37.5 K to 37.3 K (-0.53 %) |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 4,185 | 75,330 | 37,500 | 33.3 K to 37.5 K (+12.56 %) |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 3,315 | 11,934 | 33,315 | 30 K to 33.3 K (+11.05 %) |
Aug 17 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 5,047 | 90,846 | 46,852 | |
Aug 17 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 2,374 | 8,546 | 42,430 | |
Aug 17 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 79 | 284 | 62,861 | |
Aug 17 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 98.85 | 100 | 9,885 | 30,000 | 30.1 K to 30 K (-0.33 %) |
Aug 17 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 98.09 | 3,194 | 313,286 | 30,100 | 33.3 K to 30.1 K (-9.59 %) |
Aug 17 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 97.39 | 4,206 | 409,620 | 33,294 | 37.5 K to 33.3 K (-11.22 %) |
Aug 17 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 5,047 | 90,846 | 37,500 | 32.5 K to 37.5 K (+15.55 %) |
Aug 17 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 2,374 | 8,546 | 32,453 | 30.1 K to 32.5 K (+7.89 %) |
Aug 17 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 79 | 284 | 30,079 | 30 K to 30.1 K (+0.26 %) |
May 18 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 1.44 | 10,000 | 14,400 | 27,404 | |
May 18 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 64.78 | 10,000 | 647,847 | 30,000 | 40 K to 30 K (-25.00 %) |
May 18 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 1.44 | 10,000 | 14,400 | 40,000 | 30 K to 40 K (+33.33 %) |
Mar 21 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 1.44 | 25,500 | 36,720 | 37,404 | |
Mar 21 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 1.44 | 25,500 | 36,720 | 30,000 | 4.5 K to 30 K (+566.67 %) |
Mar 03 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 1.44 | 10,000 | 14,400 | 62,904 | |
Mar 03 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 1.44 | 4,500 | 6,480 | 72,904 | |
Mar 03 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 59.06 | 100 | 5,906 | 4,500 | 4.6 K to 4.5 K (-2.17 %) |
Mar 03 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 57.68 | 600 | 34,608 | 4,600 | 5.2 K to 4.6 K (-11.54 %) |
Mar 03 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 56.74 | 3,314 | 188,023 | 5,200 | 8.5 K to 5.2 K (-38.92 %) |
Mar 03 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 56.07 | 3,100 | 173,803 | 8,514 | 11.6 K to 8.5 K (-26.69 %) |
Mar 03 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 54.81 | 1,384 | 75,858 | 11,614 | 13 K to 11.6 K (-10.65 %) |
Mar 03 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 53.90 | 1,202 | 64,785 | 12,998 | 14.2 K to 13 K (-8.46 %) |
Mar 03 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 52.30 | 300 | 15,689 | 14,200 | 14.5 K to 14.2 K (-2.07 %) |
Mar 03 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 1.44 | 10,000 | 14,400 | 14,500 | 4.5 K to 14.5 K (+222.22 %) |
Mar 03 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 1.44 | 4,500 | 6,480 | 4,500 | 0 to 4.5 K |
Dec 03 2015 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | A | 63.23 | 44,500 | 2,813,735 | 44,500 | |
Nov 19 2015 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 4,615 | 83,070 | 51,899 | |
Nov 19 2015 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 4,070 | 14,652 | 44,804 | |
Nov 19 2015 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 869 | 3,128 | 62,940 | |
Nov 19 2015 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 1.44 | 10,446 | 15,042 | 77,404 | |
Nov 19 2015 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 52.01 | 1,500 | 78,012 | 0 | 1.5 K to 0 (-100.00 %) |
Nov 19 2015 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 51.24 | 18,500 | 947,877 | 1,500 | 20 K to 1.5 K (-92.50 %) |
Nov 19 2015 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 4,615 | 83,070 | 20,000 | 15.4 K to 20 K (+30.00 %) |
Nov 19 2015 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 4,070 | 14,652 | 15,385 | 11.3 K to 15.4 K (+35.97 %) |
Nov 19 2015 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 869 | 3,128 | 11,315 | 10.4 K to 11.3 K (+8.32 %) |
Nov 19 2015 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 1.44 | 10,446 | 15,042 | 10,446 | 0 to 10.4 K |
Page: 1